The dosage and administration of serplulimab (a PD‑1 inhibitor) must follow clinical guidelines strictly.
Indications
It is mainly indicated for the treatment of solid tumors (such as non‑small cell lung cancer, esophageal cancer, etc.) selected by specific genetic testing. Applicability should be confirmed based on pathological diagnosis.
Route of Administration
Intravenous infusion, once every 3 weeks. The duration of a single infusion is usually 30–60 minutes.
Recommended Dosage
Fixed dose of 300 mg, or adjusted according to body weight (e.g., 4 mg/kg). The specific regimen shall be determined by the doctor based on the patient’s condition and tolerability.
Treatment Duration
Continuous medication until disease progression, intolerable toxicity, or meeting discontinuation criteria.
Specific Instructions
1. Pre‑treatment Preparation
Complete genetic testing (e.g., MSI‑H/dMMR, PD‑L1 expression, etc.) and pathological assessment to confirm eligibility for the indication.
Evaluate the patient’s underlying diseases (e.g., autoimmune diseases, infections, etc.). The regimen should be adjusted if contraindications are present.
2. Infusion Procedure
First infusion: Recommended to be performed in a medical institution with close monitoring for hypersensitivity reactions (e.g., dyspnea, rash, etc.).
Subsequent infusions: If the previous infusion was well‑tolerated, the monitoring duration may be shortened under medical guidance.
3. Dosage Adjustment
If ≥ Grade 3 adverse reactions (e.g., immune‑mediated pneumonitis, hepatitis) occur, the drug should be suspended and symptomatic treatment given. After recovery, dose reduction or discontinuation may be considered under medical supervision.
No routine dose adjustment is needed for patients with hepatic or renal impairment, but enhanced monitoring is required.
4. Precautions
Immune‑related adverse reactions: May affect organs including the lung, liver, thyroid, etc. Regular tests of relevant indicators (e.g., liver function, thyroid function) are necessary.
Infection risk: Avoid live vaccines during treatment. Seek medical help immediately if symptoms such as fever develop.
Pregnancy and lactation: May affect fetal development. Strict contraception is required during treatment; contraindicated in breastfeeding women.
Important Note
Serplulimab is a prescription drug. Its specific use must be based on individualized assessment. Patients should attend regular follow‑ups and strictly follow medical advice during treatment. Do not adjust the dose or stop the drug without authorization. Seek emergency medical care if severe side effects occur (e.g., persistent diarrhea, hemoptysis, etc.).
